IDH2 and leukemia: Although our patient had not been treated with any IDH inhibitor, this finding is consistent with the observation reported by other investigators, describing the emergence of other IDH mutations as a resistance mechanism in IDH-mutant leukemias treated with selective IDH-inhibitors; this either indicates newly developed resistance mutations or the expansion of co-existing but sub-clonal IDH mutations [46,47].